Long-term stability of bronchial responsiveness to histamine

EF JUNIPER, PA FRITH, FE HARGREAVE

From the Firestone Regional Chest and Allergy Unit, Department of Medicine, St Joseph's Hospital and McMaster University, Hamilton, Ontario, Canada

ABSTRACT Bronchial responsiveness to histamine was measured in 35 adult asthmatics whose symptoms were controlled on a minimum of medication. The tests were carried out on two occasions separated by 10-30 months. On each occasion the subjects had no symptoms of respiratory infection and no exposure to relevant allergens for at least six weeks. Bronchial responsiveness did not change in those who required no medication or inhaled salbutamol only to control their symptoms, but was significantly improved in those who required continuous treatment with both beclomethasone and salbutamol (p = 0.03). The results suggest that non-specific bronchial responsiveness remains similar over long periods when exacerbating factors are not present and that treatment with beclomethasone may reduce hyperresponsiveness.

The degree of non-specific bronchial responsiveness to histamine or methacholine correlates with the minimum amount of medication needed to control symptoms of asthma. In general the greater the hyperresponsiveness, the more medication is required to control symptoms. Exacerbations of asthma and heightened responsiveness can be induced by viral respiratory infection and exposure to allergens or volatile low molecular weight chemicals to which the person is sensitised. These events seem to lead to a requirement for more treatment; however, once the stimulus has been removed medication requirements often return to the same level as before. These points suggest that if non-specific bronchial responsiveness is measured when exacerbating factors are not present it should remain stable over long periods of time.

In this study we have examined the long-term stability of bronchial responsiveness to histamine in 35 adults with asthma. Measurements were made on two occasions separated by an interval of 10-30 months when symptoms were controlled by a minimum of medication and when symptoms of respiratory infection or exposure to allergen had not occurred for at least six weeks.

Methods

The subjects were 35 of 51 adults with asthma who participated in an earlier study (table 1). All had previous or current episodic dyspnoea and wheezing and, from review of their records, showed variability in forced expired volume in one second (FEV1) of more than 20%. Ten were atopic as indicated by one or more wheal and flare responses to skin prick tests with 16 common allergen extracts. All were non-smokers and none had features of other respiratory disease.

At the time of study their symptoms were controlled on a minimum of medication. Nine required no medication, 11 needed inhaled salbutamol (200 μg) at least once a week up to four times a day, and 15 required additional beclomethasone dipropionate (100 μg) once to four times a day. FEV1 was greater

Table 1 Patient characteristics

<table>
<thead>
<tr>
<th>No medication</th>
<th>Salbutamol</th>
<th>Beclomethasone + salbutamol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>9</td>
<td>11</td>
</tr>
<tr>
<td>Age (yr) Mean</td>
<td>30.3</td>
<td>41.0</td>
</tr>
<tr>
<td>SD</td>
<td>6.5</td>
<td>11.4</td>
</tr>
<tr>
<td>Female Initial FEV1 (%) predicted</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Mean</td>
<td>95.9</td>
<td>96.4</td>
</tr>
<tr>
<td>SD</td>
<td>7.4</td>
<td>10.8</td>
</tr>
<tr>
<td>Atopic*</td>
<td>7</td>
<td>3</td>
</tr>
</tbody>
</table>

*Indicated by one or more wheal and flare responses to skin prick tests with 16 common allergens.
than 70% of predicted in all but five subjects at the time of the first inhalation test; in these it rose to above 80% predicted after salbutamol (200 μg). No patients had symptoms of respiratory infection or exposure to an allergen to which they were sensitised for six weeks before each test.

**Histamine Inhalation Test**
The test was carried out by the method described by Cockcroft et al. Aerosols of the test solution were generated by a Wright nebuliser operated to give an output of 0.13 ml/min and a particle size of 1.5 μm aerodynamic mass median diameter. Each aerosol was inhaled through the mouth by tidal breathing for two minutes. The first aerosol was saline and it was followed at five-minute intervals by two-fold increasing concentrations of histamine acid phosphate (0.03 to 16 mg/ml). The response was measured by the FEV1 at 0.5 and 1.5 min after each inhalation and further two-minute intervals if necessary to record the lowest value.

Inhalations were discontinued when the FEV1 had fallen 20% or more below the lowest post-saline value. The results were expressed as the provocation concentration causing a fall in FEV1 of 20% (PC20). This was obtained by linear interpolation of the last two points on the log dose-response curve.

**Study Design**
A histamine inhalation test was carried out on two occasions separated by a period of at least 10 months. Before the initial test, the minimum medication requirements to control symptoms were established in a standard manner in every subject. Subjects remained on this level of treatment between the two tests unless there were exacerbations of symptoms, usually caused by allergen exposure or upper respiratory tract infection. Medications were increased to treat these; however when the provocation had been removed, treatment was reduced to the previously established minimum. All subjects required only their minimum medication requirements for at least six weeks before each test. On the test days, salbutamol was withheld for eight hours before inhalation but beclomethasone was continued in the regular dose.

**Table 2 Summary of results**

<table>
<thead>
<tr>
<th></th>
<th>No medication</th>
<th>Salbutamol</th>
<th>Beclomethasone + salbutamol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time between tests (months)</td>
<td>16.6</td>
<td>13.5</td>
<td>22.1</td>
</tr>
<tr>
<td>Initial PC20 (mg/ml)</td>
<td>Mean 6.07</td>
<td>2.45</td>
<td>0.50</td>
</tr>
<tr>
<td></td>
<td>SD 4.26</td>
<td>1.80</td>
<td>0.49</td>
</tr>
<tr>
<td>Final PC20 (mg/ml)</td>
<td>Mean 7.69</td>
<td>3.02</td>
<td>1.23</td>
</tr>
<tr>
<td></td>
<td>SD 3.58</td>
<td>2.73</td>
<td>1.26</td>
</tr>
<tr>
<td>Initial FEV1 (l)</td>
<td>Mean 2.89</td>
<td>2.98</td>
<td>2.09</td>
</tr>
<tr>
<td></td>
<td>SD 0.71</td>
<td>0.66</td>
<td>0.71</td>
</tr>
<tr>
<td>Final FEV1 (l)</td>
<td>Mean 2.88</td>
<td>2.95</td>
<td>2.45</td>
</tr>
<tr>
<td></td>
<td>SD 0.81</td>
<td>0.72</td>
<td>0.74</td>
</tr>
</tbody>
</table>

**Fig 1 Changes in bronchial responsiveness to histamine over 10-30 months. Crosses (+) represent patients on no medications, open circles (○) those requiring salbutamol alone, and closed circles (●) those requiring daily beclomethasone and salbutamol. The dashed line is the line of identity and the solid lines ± one two-fold concentration of histamine.**
ANALYSIS

The changes in bronchial responsiveness between the two tests were examined using paired t tests and significant changes were compared with other variables using correlation coefficient.

Results

The length of time between the two tests ranged from 10-30 months. Bronchial responsiveness to histamine (expressed as PC_{20}) in the first test was compared to that measured in the second test (table 2, fig 1). There was no difference in patients on no medication (p > 0.05) and in those only requiring salbutamol (p > 0.1). There was a decrease in hyperresponsiveness (increase in PC_{20}) in those on beclomethasone (p = 0.03).

The reduction in hyperresponsiveness, in patients on beclomethasone, was weakly related to the changes in baseline FEV_{1} (r = 0.45) (fig 2) and to the length of time between the two tests (r = 0.21).

Discussion

In the present study bronchial responsiveness to histamine in mild asthmatics, who required no medication or only salbutamol to control symptoms, did not alter over 10-30 months. Bronchial responsiveness in more severe asthmatics, requiring treatment with additional beclomethasone, improved slightly.

The first observation supports the contention that the degree of non-specific bronchial responsiveness, in individual adults with asthma, remains similar over long periods when symptoms are controlled and exacerbating factors are not present. It is known that respiratory infection\textsuperscript{8} and allergen exposure\textsuperscript{8} generally only heighten responsiveness for short periods, although there is suggestive evidence that these stimuli may induce more permanent changes. For example, intrinsic asthma beginning in adult life may follow an acute respiratory infection\textsuperscript{9} and patients with occupational asthma after sensitisation to western red cedar, can remain symptomatic and have non-specific bronchial hyperresponsiveness long after exposure has been discontinued.\textsuperscript{10} The observations in the present study therefore cannot be extended to indicate that bronchial responsiveness will always remain similar; increases or decreases in hyperresponsiveness may occur for long periods although they did not occur in the present study.

Treatment with salbutamol will decrease bronchial responsiveness acutely\textsuperscript{11} and must therefore be withheld before its measurement. There is also a possibility that regular use of salbutamol may decrease \beta-receptor function in bronchial smooth muscle,\textsuperscript{12} and this may lead to an increase in bronchial responsiveness.\textsuperscript{13} The results of the present study make this unlikely since responsiveness did not increase in patients whose asthma required treatment with salbutamol alone; this agrees with the findings of Peel and Gibson.\textsuperscript{14}

The second observation raises the possibility that in more severe asthma, treatment with beclomethasone may reduce hyperresponsiveness. One cannot be certain about the validity of this result since the significance was not great and the study was not designed to examine this point. Previous reports of the effect of corticosteroids on bronchial responsiveness to histamine or methacholine have tended to suggest that they have little or no effect,\textsuperscript{15-17} and one even described an increase in responsiveness.\textsuperscript{18} However, these observations could be a result of subject selection and study design. An
improvement in non-specific bronchial responsiveness might be expected where the corticosteroids are reversing changes which might contribute to the increase in responsiveness. These might include reduction in secretions tending to reduce airway calibre, reversal of epithelial shedding which might expose irritant receptors and increase reflex cholinergic bronchoconstriction, reduction of mucosal oedema and permeability, reduction of inflammatory reaction, and increase in the number of \( \beta \)-adrenoceptors on smooth muscle. Alternatively the reduction in hyperresponsiveness may not be the result of an effect of beclomethasone but rather of spontaneous reduction in the degree of bronchial smooth muscle constriction at the time of the second test.

There was a weak relationship between improvement in bronchial responsiveness and increase in baseline FEV1. This could mean that the former influenced the latter or vice versa. However, the relationship was primarily caused by the influence of three of the 15 patients on beclomethasone who increased both PC20 and FEV1 significantly; two patients had a significant increase in FEV1 but no change in PC20. It is therefore difficult to draw conclusions on the interrelationship of bronchial responsiveness and airway calibre.

We are grateful to our patients for participating in the study, and to Dr NL Jones and Dr J Dolovich for help with preparing the manuscript. This work was supported by a grant from the Medical Research Council of Canada.

References

9 Rackemann FM. Intrinsic asthma. J Allergy 1940;11:147-62.